Saudi German Health Swings to 36.7M SAR Profit

Riyadh, Saudi Arabia — Middle East Healthcare Company, known as Saudi German Health, returned to profit in Q3 2026, booking a net profit attributable to shareholders of 36.68 million SAR. That compares with a restated net loss of 89.66 million SAR in the same quarter last year — a dramatic reversal driven by revenue growth, cost discipline, and a significant restatement of prior-period figures. Quarter-on-quarter, net profit rose 6.8% from 34.35 million SAR in Q2 2026.

For the nine-month period ending 30 September 2026, Saudi German Health reported cumulative net profit of 104.49 million SAR, up 8.3% from 96.46 million SAR in the same period last year. Revenue for the nine months reached 2,487.9 million SAR, an 8.5% increase year-on-year. Earnings per share stood at 1.14 SAR, up from 1.05 SAR a year earlier.

Quarterly and Period Breakdown

Q3 2026 revenue reached 877.15 million SAR, up 14.1% from 768.89 million SAR in Q3 2025 and up 3.7% from 845.52 million SAR in Q2 2026. Gross profit held near flat year-on-year at 283.4 million SAR versus 281.78 million SAR, while operational profit surged to 96.93 million SAR from an operating loss of 33.13 million SAR a year ago. Gross margin in Q3 2026 improved to 32.3%, up from 31.5% in Q2 2026, driven by a higher mix of subspecialty procedures.

Over the full nine-month period, gross profit declined 7.1% to 811.95 million SAR from 873.54 million SAR. That dip reflects the prior period’s one-off 114.5 million SAR gain on a Riyadh land sale, which inflated last year’s comparative base. Operational profit for the period rose modestly to 275.6 million SAR, up 2% from 270.18 million SAR. Total shareholders’ equity grew 6.6% to 1,536.98 million SAR.

Key Drivers

• Revenue growth: Inpatient revenue rose 12.2% (155.8 million SAR) and outpatient revenue grew 5.6% (39.1 million SAR) over the nine-month period, led by expanded surgical and specialized care services.
• Restatement effect: The prior-year quarter included a 134.2 million SAR impairment of reinstated trade receivables. The nine-month comparative included a 184.2 million SAR charge. Neither recurred in 2026, boosting the year-on-year comparison.
• Cost control: General, administrative, selling, and marketing expenses fell as a percentage of revenue, reflecting overhead discipline across the group.
• Lower finance and zakat costs: Finance costs dropped 5.4% (7.8 million SAR) over the nine months; zakat expense fell by 3.7 million SAR.
• Partial offsets: Non-cash losses on hedging contracts pushed finance costs higher in Q3. The share of loss from associate Al Sobh Investment Holding rose to 18.5 million SAR from 2.6 million SAR in the prior period.

Auditor Qualification

Saudi German Health’s external auditor issued a qualified conclusion on the interim financials. The auditor flagged that it could not obtain sufficient evidence to evaluate the restatement disclosed in Note 24 — specifically adjustments to property and equipment, depreciation, trade receivables, expected credit loss allowances, and retained earnings. As a result, the auditor could not determine whether further adjustments to the comparative figures were necessary. This qualification applies to periods ending 31 December 2024 and 31 December 2025, as well as the nine months ended 30 September 2026.

The auditor also drew attention to related-party transactions with entities under common control, as described in Note 16. Investors should treat the restated comparative figures with appropriate caution until the restatement is fully resolved and independently verified.

What This Means for Investors

• The profit recovery is real but context matters: The swing from loss to profit is partly mechanical — last year’s quarter carried a 134.2 million SAR one-off impairment. Underlying operational improvement is genuine but more modest.
• Auditor qualification is a red flag: When auditors cannot verify a restatement, the reliability of comparative data is compromised. Investors should monitor resolution of Note 24 closely.
• Al Sobh remains a drag: The associate’s 18.5 million SAR loss contribution is significant. Management expects gradual improvement as operations — which began in Q4 2025 — mature.
• Revenue momentum is solid: Double-digit surgical volume growth and expanding specialty services suggest the core hospital business is strengthening, which supports a constructive medium-term view if governance concerns are addressed.

Latest Saudi stock market investor news and company announcements

Saudi Arabia capital markets coverage and analysis

THE SAUDI STANDARD’S VIEW: SAUDI GERMAN HEALTH’S PROFIT RECOVERY DEMANDS SCRUTINY BEFORE CELEBRATION

Saudi German Health’s return to profitability is a headline that warrants careful unpacking. The swing from deep loss to positive earnings reflects a combination of genuine operational progress and significant accounting adjustments, and investors must weigh both with equal discipline before drawing portfolio conclusions.

• OPERATIONAL RECOVERY IS REAL, BUT STRUCTURALLY PARTIAL

Double-digit inpatient revenue growth and expanding subspecialty surgical volumes confirm that the core hospital business is generating genuine commercial momentum. However, the year-on-year profit comparison is materially flattered by the non-recurrence of large prior-period impairment charges, which means the underlying earnings improvement is more measured than the headline figures suggest. Investors should anchor their assessment to sequential quarterly trends rather than year-on-year comparisons until the restated base is fully stabilized.

• AUDITOR QUALIFICATION INTRODUCES MATERIAL GOVERNANCE RISK

An external auditor’s inability to verify a restatement spanning multiple financial periods is not a procedural footnote — it is a substantive governance signal that demands investor attention. Until the adjustments to property, equipment, depreciation, and receivables are independently confirmed, the reliability of the comparative financial framework remains in question. For institutional investors with fiduciary obligations, this qualification alone may warrant a cautious position until resolution is confirmed.

• AL SOBH ASSOCIATE LOSSES REPRESENT A GROWING EARNINGS DRAG

The sevenfold increase in losses attributable to associate Al Sobh Investment Holding introduces a structural earnings dilutant that warrants monitoring as a distinct risk factor. Early-stage operations carry expected losses, but the magnitude of this drag relative to the group’s quarterly profit underscores how dependent overall earnings improvement is on this entity’s maturation timeline. Management’s forward guidance on Al Sobh’s operational trajectory will be a key variable in any earnings forecast revision.

• MARGIN DISCIPLINE OFFERS THE MOST DURABLE POSITIVE SIGNAL

The sequential improvement in gross margin, driven by a higher-value procedural mix, demonstrates that Saudi German Health is not merely growing revenue but improving the quality of that revenue. Combined with measurable reductions in overhead as a share of sales and declining finance and zakat costs, the group’s cost management posture reflects strategic discipline rather than cyclical luck. This structural margin trajectory, if sustained, represents the most credible foundation for a medium-term investment thesis.

Saudi German Health operates at the intersection of two of Vision 2030’s most consequential pillars — healthcare localization and private sector expansion. The Kingdom’s strategic ambition to reduce dependence on public healthcare delivery and attract world-class medical investment creates a structurally favorable operating environment for scaled private hospital groups. Saudi German Health’s expanding surgical capabilities and specialty service mix position it to benefit directly from this transformation. However, Vision 2030’s healthcare objectives demand not only operational scale but institutional credibility — and resolving the current auditor qualification is not merely a compliance exercise but a prerequisite for the company to fully claim its role as a flagship of Saudi Arabia’s privatized healthcare future.